Life sciences merger and acquisition spending surges as large deals make a comeback according to EY
Global life sciences mergers and acquisitions (M&A) spending experienced a significant increase in 2025, reaching $240 billion, which represented an 81% surge from the previous year’s total of $130 billion. Despite a decrease in the overall number of transactions by 12%, the industry saw a boost in financial activity due to large pharmaceutical companies engaging in high-value acquisitions. The biopharma sector witnessed a decline in deal volume by 19%, while medtech experienced a 6% increase. The escalation in spending was predominantly driven by a surge in the average deal size, which rose by 107% to $2.1 billion.
Subin Baral, EY-Parthenon’s global head of life sciences deals, emphasized the resilient nature of the sector, citing factors such as expiring patents and ample capital availability as key driving forces behind the continued financial momentum. However, Baral also highlighted persistent challenges facing the industry, including regulatory and geopolitical uncertainties, soaring valuations, and competing capital demands. These factors underscore the delicate balance that companies in the life sciences sector must navigate as they pursue growth opportunities and strategic acquisitions.
The substantial increase in M&A spending reflects the industry’s strategic shift towards consolidation and strategic partnerships, as companies seek to enhance their product portfolios, expand market presence, and drive innovation through inorganic growth. The rise in deal sizes signifies a willingness among industry players to invest in transformative transactions that have the potential to reshape the competitive landscape and drive long-term value creation.
While the overall deal volume may have declined, the uptick in spending signals a profound confidence in the future outlook of the life sciences sector, with companies willing to commit substantial resources to capitalize on emerging opportunities and address evolving market dynamics. The increased focus on large-scale acquisitions underscores the industry’s commitment to driving innovation, fostering collaboration, and delivering value to stakeholders across the healthcare ecosystem.
As the industry continues to evolve, companies must remain vigilant in navigating the complex landscape of regulatory, market, and technological challenges that impact their strategic decisions. By staying attuned to emerging trends, regulatory developments, and market dynamics, industry players can position themselves for sustainable growth and long-term success in an increasingly competitive and dynamic environment.
In conclusion, the surge in global life sciences M&A spending in 2025 underscores the industry’s resilience, strategic agility, and commitment to driving innovation and value creation. Despite facing headwinds such as regulatory uncertainties and high valuations, companies remain optimistic about the future outlook of the sector and are actively pursuing transformative transactions to position themselves for long-term success in an evolving healthcare landscape.